Hollis-Eden Names Frincke CEO
San Diego’s Hollis-Eden Pharmaceuticals (NASDAQ: HEPH) today named James Frincke as CEO, three months after the biotech terminated founder Richard Hollis. Frincke, who was the biotech’s chief operating officer, was named interim CEO at the time. Hollis founded the biotech 15 years ago to develop therapies based on a synthetic form of HDEA, an adrenal hormone that helps strengthen the body’s immune system. Frincke, a 28-year veteran of the biotech industry, has managed a variety of product development programs.